Agilent Technologies Inc
NYSE:A
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.2B USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
148.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
136.7T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.1B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
284.7B CNY |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.1B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.9B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
168B HKD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
17.8B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Agilent Technologies Inc
Glance View
Agilent Technologies Inc., a spin-off from Hewlett-Packard in 1999, has cultivated a niche in the vibrant landscape of the life sciences, diagnostics, and applied chemical markets. This California-based company, born from the legacy of one of Silicon Valley’s pioneers, has carved out its identity by providing sophisticated analytical instrumentation, software, services, and consumables for a wide range of applications. Agilent's businesses are stitched together by an underlying technology expertise, which forms the bedrock for its product lines that serve an increasing demand for precise and reliable analytical measurements. From cutting-edge liquid chromatography to mass spectrometry and genetic analysis systems, Agilent's offerings are geared towards supporting research and quality control processes across various industries, including pharmaceuticals, food safety, and environmental testing. The company's commitment to innovation and quality has consistently positioned it as a trusted partner in advancing the capabilities of laboratories worldwide. Agilent's revenue generation hinges on a strategic blend of product sales and services. The core of its business model revolves around not just selling instruments, but also establishing long-term relationships through service agreements, maintenance, and training. This recurring service revenue complements the sale of consumables and parts required for the operation of their sophisticated instruments. Additionally, Agilent has strategically expanded its footprint in the diagnostics market, providing instruments and reagents used in pathology laboratories, further diversifying its income streams. With a deliberate focus on high-growth areas, including genomics and cancer diagnostics, Agilent continues to leverage its technological prowess and industry expertise to capture market share in sectors that are inherently driven by the necessity for innovation and regulatory compliance. Through an intricate balance of hardware sales and consistent after-sale support, Agilent steadily maintains its role as a formidable player in the analytical instrumentation sector.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Agilent Technologies Inc is 52.7%, which is below its 3-year median of 52.9%.
Over the last 3 years, Agilent Technologies Inc’s Gross Margin has decreased from 54.4% to 52.7%. During this period, it reached a low of 50.7% on Jan 31, 2024 and a high of 54.7% on Jul 31, 2024.